GlassScriptPhysician profile
Aniqa A Kohen
NPI 1831531995
$782.81
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $76.40 · 2021: $537 · 2022: $169.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $136.90 | 2021 | |
| Janssen Scientific Affairs, LLC | $124.99 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $123.03 | 2022 | |
| Janssen Biotech, INC. | $113.30 | 2021 | |
| Erbe USA INC | $88.00 | 2021 | |
| Abbvie INC. | $52.32 | 2020-2022 | |
| Redhill Biopharma INC. | $48.11 | 2020 | |
| Intercept Pharmaceuticals, INC. | $30.44 | 2020-2022 | |
| Qol Medical, LLC | $22.66 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.94 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.68 | 2022 | |
| Celgene Corporation | $11.44 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aniqa Kohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.